HCC CONNECT has summarised the highlights from ESMO 2018 for you


Hepatocellular carcinoma by Dr. Changhoon Yoo, Asan Medical Center, University of Ulsan College of Medicine, Korea

 

Dr Changhoon Yoo is a medical oncologist who specialises in the care of patients with gastrointestinal cancers including hepatocellular carcinoma. He is an Assistant Professor at Asan Medical Center in Seoul, South Korea. Dr Yoo obtained his medical degree at the University of Ulsan College of Medicine, Seoul, South Korea and completed post graduate training at Asan Medical Center. He has participated in multiple clinical trials and translational research for the development of novel agents for patients with hepatocellular carcinoma. His research initiatives include the integration of novel targeted and immune-based therapy into the treatment of hepatocellular carcinoma. Relevant publications Kim HD, Song GW, Park S, Jung MK, Kim MH, Kang HJ, Yoo C, Yi K, Kim KH, Eo S, Moon DB, Hong SM, Ju YS, Shin EC, Hwang S, Park SH. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma. Gastroenterology 2018 Aug 23; pii: S0016-5085(18)34897-2. doi: 10.1053/j.gastro.2018.08.030. [Epub ahead of print] PMID: 30145359 Yoo C, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, Kim TY, Ryoo BY. Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat 2018 Jun 13. doi: 10.4143/crt.2018.226. [Epub ahead of print] PMID: 29898591 
Chae H, Cho H, Yoo C, Kim KP, Jeong JH, Chang HM, Kang J, Lee HC, Lim YS, Kim KM, Shim JH, Lee SS, Park DH, Song TJ, Hwang S, Song GW, Moon DB, Lee YJ, Lee JH, Ryoo BY. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. Int J Biol Markers 2018 Jun 1:1724600818777239. doi: 10.1177/1724600818777239. [Epub ahead of print] PMID: 29874985 
Cho H, Yoo C, Kim KP, Jeong JH, Kang J, Chang HM, Lee SS, Park DH, Song TJ, Lee SK, Kim MH, Lee HC, Lim YS, Kim KM, Shim JH, Hwang S, Song GW, Moon DB, Lee JH, Lee YJ, Ryoo BY. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. Invest New Drugs 2018 Jun;36(3):496-502. doi: 10.1007/s10637-017-0548-7. Epub 2017 Dec 1. PMID: 29192354 Yoo C, Kang J, Kim D, Kim KP, Ryoo BY, Hong SM, Hwang JJ, Jeong SY, Hwang S, Kim KH, Lee YJ, Hoeflich KP, Schmidt-Kittler O, Miller S, Choi EK. Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. Oncotarget 2017 Jun 13;8(24):38592-38601. doi: 10.18632/oncotarget.16951.

Asst. Prof. Changhoon Yoo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Eisai, MSD, Ono and Ipsen.

HCC CONNECT Update from ESMO 2019

HCC CONNECT has summarised highlights of the recent ESMO 2019 meeting for you

Experts
Dr Su Pin Choo
  • download Downloadable
    Resouces
  • clock 5 MIN
  • calendar Sep 2021
  • Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from Bayer
HCC CONNECT Update from ILCA and ESMO 2020

HCC CONNECT has summarised the highlights from ILCA and ESMO 2020 for you.Liver Cancer update by Dr. Su Pin Choo, Curie Oncology and National Cancer Centre, Singapore

Experts
Dr Su Pin Choo
  • download Downloadable
    Resouces
  • clock 5 MIN
  • calendar Sep 2021
  • Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from Bayer
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast

Episode

4

of 4

episode
Oncology 
HCC podcast series part 4: Intermediate HCC – the evolving role of IO

Integrating multimodal approaches with multidisciplinary care

Experts
Dr Edward Kim, Dr Nina Sanford, Dr Mark Yarchoan, Oncology Brothers (Moderators)
Endorsed by
Blue Faery plus Global Liver Institute DiCE
ELPA
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
video Video
Oncology 
The evolving role of liquid biopsy in HR+/HER2- metastatic breast cancer

Exploring the impact of liquid biopsy in advanced breast cancer

Experts
Prof. Frédérique Penault-Llorca, Dr Aditya Bardia
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
animated-video Animated Video
Oncology Obstetrics and Gynecology 
Current treatment options in advanced/recurrent endometrial cancer

Exploring the impact of molecular subtypes 

Experts
Prof. Christian Marth
  • download Downloadable
    Resources
  • clock 7 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme.
podcast Podcast

Episode

3

of 4

episode
Oncology 
HCC podcast series part 3: Intermediate HCC – treatment options and strategies

Expert insights on systemic, loco-regional, and multimodal therapies

Experts
Dr Maria Reig, Dr Emil I Cohen, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
ELPA
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Recent advances in precision oncology and future implications

Two emerging and two established targets

Experts
Prof. David Hong
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Announcing the publication of survey results 

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.